TADG-15 and Ovarian Cancer
Author Information
Author(s): Tanimoto H, Shigemasa K, Tian X, Gu L, Beard J B, Sawasaki T, O'Brien T J
Primary Institution: Hiroshima University Graduate School of Biomedical Sciences
Hypothesis
TADG-15 may have prognostic value as an ovarian cancer biomarker.
Conclusion
Increased expression of TADG-15 is associated with early stage ovarian cancer and longer patient survival.
Supporting Evidence
- TADG-15 was expressed in 50 (56.2%) of 89 ovarian carcinomas.
- TADG-15 expression was significantly more common in patients with early stage disease.
- Patients with TADG-15-positive tumours had substantially longer survival.
Takeaway
TADG-15 is a protein that can help doctors tell if ovarian cancer is in an early stage, which is better for patients.
Methodology
Immunohistochemical study and semiquantitative PCR were used to assess TADG-15 expression in ovarian cancer specimens.
Limitations
The study did not examine the expression of TADG-15's inhibitor, HAI-1.
Participant Demographics
Mean age of participants was 51.3 years, with a range from 23 to 80 years.
Statistical Information
P-Value
P=0.0157
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website